Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.

Aclaris Therapeutics Inc

ACRS
4,01
-0,31 (-7,18%)
23 Nov 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
22/11/202422:00EDGAR2Form SC 13G - Statement of Beneficial Ownership by Certain..
21/11/202422:51EDGAR2Form SC 13G - Statement of Beneficial Ownership by Certain..
20/11/202422:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/11/202422:05APSThis Healthcare Stock Soared Following Exclusive License..
18/11/202422:20EDGAR2Form 3 - Initial statement of beneficial ownership of..
18/11/202414:50PRNUSBiosion Announces Exclusive, Global License Agreement with..
18/11/202414:15EDGAR2Form 8-K - Current report
18/11/202414:10GLOBEAclaris Therapeutics Announces $80 Million Private Placement
18/11/202414:10GLOBEAclaris Therapeutics Announces Exclusive, Global License..
06/11/202422:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/11/202413:21EDGAR2Form 8-K - Current report
06/11/202413:00GLOBEAclaris Therapeutics Reports Third Quarter 2024 Financial..
05/11/202422:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/10/202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/9/202413:00GLOBEAclaris Therapeutics Announces First Patient Dosed in Phase..
10/9/202413:00GLOBEAclaris Therapeutics to Participate in the 2024 Cantor..
05/9/202401:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/9/202423:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/8/202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/8/202413:15EDGAR2Form 8-K - Current report
07/8/202413:00GLOBEAclaris Therapeutics Reports Second Quarter 2024 Financial..
05/8/202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/7/202422:30EDGAR2Form 8-K - Current report
16/7/202422:01GLOBEAclaris Therapeutics Announces Sale of OLUMIANT® Royalties..
10/6/202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/6/202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/6/202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/6/202422:15EDGAR2Form 8-K - Current report
06/6/202413:00GLOBEAclaris Therapeutics to Participate in the Goldman Sachs..
04/6/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/6/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/6/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/6/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/5/202422:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/5/202422:15EDGAR2Form 8-K - Current report
07/5/202422:06EDGAR2Form S-8 - Securities to be offered to employees in employee..
07/5/202422:01GLOBEAclaris Therapeutics Reports First Quarter 2024 Financial..
30/4/202413:00GLOBEAclaris Therapeutics to Announce First Quarter 2024..
23/4/202414:00PRNUSFlare Therapeutics Appoints Douglas Manion, M.D., FRCP (C)..
05/3/202423:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202423:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202423:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202413:30EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
27/2/202413:14EDGAR2Form 8-K - Current report
27/2/202413:00GLOBEAclaris Therapeutics Reports Fourth Quarter and Full Year..
15/2/202402:32EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202420:06EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
13/2/202420:24EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
06/2/202401:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/2/202401:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
Apertura: 4,28 Min: 3,84 Max: 4,44
Chiusura: 4,32

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network